Merck & Company (MRK) stock had a bullish inflow of $37.35 million worth of trades on uptick and an outflow of $34.99 million in downticks on Thursday. The total uptick to downtick ratio stood at 1.07. The net money flow into the stock was $2.35 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $4.8 million. An inflow of $7.45 million block trade was recorded on downticks. $12.25 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 1.64 in favor of the bulls. However, Merck & Company (MRK) stock traded down $0.06 , and reached $59.5, a drop of -0.09% over the previous day. On a weekly basis, the stock is 0.24%, over the previous weeks close.
The stock has recorded a 20-day Moving Average of 3.76% and the 50-Day Moving Average is 6.39%. Shares have rallied 1.98% from its 1 Year high price. On Aug 19, 2015, the shares registered one year high at $60.07 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $56.90 and the 200 Day Moving Average price is recorded at $53.82.
Merck & Company (NYSE:MRK): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $59.87 and $59.48 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $59.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $59.65, notching a gain of 0.17% for the day. The total traded volume was 7,345,481 . The stock had closed at $59.55 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged that Graddick Weir Mirian M, officer (Exe V-P, HR) of Merck & Co., Inc., had unloaded 45,000 shares at an average price of $57.96 in a transaction dated on July 5, 2016. The total value of the transaction was worth $2,608,200.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.